May 4, 2004--BTG (LSE:BGC), the intellectual property and technology commercialization company, announced today that it has acquired two innovative drug discovery programs from King’s College London. These acquisitions will strengthen BTG’s portfolio in the areas of diabetes and neurodegeneration -- two major focus areas of BTG’s Ageing & Neuroscience Business Unit.
